Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Veronica Green

Physician Assistant Brooklyn, NY Physician Assistant

NPI 1902027261 CMS profile 10635354

4802 10Th Ave, Attention Labor And Delivery, Brooklyn, NY 11219

Open in the dashboard

General payments

$4,998

261 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Veronica Green of Brooklyn, NY is reported in the CMS Open Payments database as having received $4,998 across 261 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,817 91
2024 General $1,776 66
2023 General $975 66
2022 General $265 26
2021 General $164 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Veronica Green
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Veronica Green were reported at $1,817. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Veronica Green Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $164 $132 $37–$438 $132
2022 $265 $155 $48–$522 $149
2023 $975 $167 $52–$557 $160
2024 $1,776 $178 $55–$600 $164
2025 $1,817 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $735 78 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $605 24 payments
  3. Novo Nordisk Inc $482 15 payments
  4. Lilly USA, LLC $479 23 payments
  5. AstraZeneca Pharmaceuticals LP $468 14 payments
  6. ITI, Inc. $362 16 payments
  7. GlaxoSmithKline, LLC. $304 13 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $233 17 payments
  9. Amgen Inc. $175 11 payments
  10. Ardelyx, Inc. $174 5 payments
  11. Other $982 45 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,991 260 payments
  2. Education $7 1 payment
Products named General payments · program years 2021–2025
  1. Kerendia $605 24 payments
  2. UBRELVY $458 43 payments
  3. CAPLYTA $362 16 payments
  4. TRELEGY ELLIPTA $304 13 payments
  5. BREZTRI $275 9 payments
  6. Ozempic $260 9 payments
  7. QULIPTA $254 23 payments
  8. JARDIANCE $237 9 payments
  9. XIFAXAN $233 17 payments
  10. MOUNJARO $225 13 payments
  11. Other $2,624 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

1,386

Median for Physician Assistant: 241

Drug cost

$93,574

Median for Physician Assistant: $4,110

Branded share of claims

13.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 29 $26,988
Trulicity Dulaglutide Brand 17 $26,872
Jardiance Empagliflozin Brand 16 $20,249
Linzess Linaclotide Brand 14 $9,642
Gabapentin Generic 75 $1,101
Albuterol Sulfate Hfa Albuterol Sulfate Brand 37 $880
Atorvastatin Calcium Generic 79 $534
Levetiracetam Generic 14 $474
Cephalexin Generic 15 $376
Diclofenac Sodium Generic 28 $343

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $363
$363 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $160
$160 — —
IBSRELA
  • Ardelyx, Inc. $152
$152 — —
JARDIANCE
  • Lilly USA, LLC $126
  • Boehringer Ingelheim Pharmaceuticals, Inc. $18
$143 16 —
REXULTI
  • Lundbeck LLC $56
  • Otsuka America Pharmaceutical, Inc. $51
$107 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record